View in EDS

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

Saved in:
Bibliographic Details
Title: Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.
Authors: Wainberg ZA; University of California, Los Angeles Los Angeles, CA United States., Lee KW; Seoul National University Bundang Hospital Seongnam, Gyeongi Korea (South), Republic of., Kim JG; Kyungpook National University Chilgok Hospital Daegu Korea (South), Republic of., Devoe C; Zucker School of Medicine at Hofstra/Northwell Lake Success, NY United States., Strickler JH; Duke University Durham, NC United States., Baum J; Leap Therapeutics Cambridge, MA United States., Jia C; Leap Therapeutics, Inc. (United States)., Kagey MH; Leap Therapeutics, Inc. (United States)., Sirard CA; Leap Therapeutics, Inc. (United States)., Stein A; University Medical Center Hamburg-Eppendorf Hamburg, Hamburg Germany., Scott AJ; Banner University of Arizona Cancer Center Tucson, AZ United States., Pelster M; Tennessee Oncology Nashville, Tennessee United States., Moehler M; University of Mainz Mainz Germany., Han SW; Seoul National University Hospital Seoul Korea (South), Republic of.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Jul 23. Date of Electronic Publication: 2026 Jul 23.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-26-1456